Clinical Trial Update: Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis [Phase 2]

View source ↗

Summary

Open-label extension of Opexa Therapeutics' TERMS Phase 2 trial for relapsing forms of multiple sclerosis was terminated, with results posted in 2016. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clinically Isolated Syndrome
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tovaxin

Snippet

Sponsor: Opexa Therapeutics, Inc. | Conditions: Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2016-03-15